Skip To Main Content
A. Moskowitz on Muck Rack

A. Moskowitz

As seen in: Color Research & Application, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to A. Moskowitz’s profile

Articles by A. Moskowitz

PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin Lymphoma

|
By A. Moskowitz, K. L. Savage, N. Muthukrishnan Ganesan, T. Feldman
| Wiley Online Library Verified
Introduction: Interim PET is highly predictive of outcome for patients (pts) with stage III or IV Hodgkin lymphoma (HL) treated with 6 cycles of Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD). The RATHL study showed that PET-2 negative (neg) pts receiving 6 cycles of ABVD can stop bleomycin after 2 cycles without compromising efficacy. Furthermore, PET-2 positive (pos) pts appear to have improved outcomes if treatment is intensified with BEACOPP (Johnson, et al. NEJM 2016).
Open in Who Shared Issue with article?

The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?

|
By S. Geller, P. L. Myskowski, Y. Kim, A. Moskowitz
| Color Research & Application Verified
Conflicts of interest: Y.H.K. is a member of a steering committee and advisory board for Eisai; has received research funding from and is an advisory board member for Forty Seven Inc.
Open in Who Shared Issue with article?

The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: Are we there yet?

|
By S. Geller, Y. Kim, P. L. Myskowski, A. Moskowitz, S. Horwitz
| Color Research & Application Verified
Brentuximab vedotin (BV) is an anti-CD30 antibody–drug conjugate that is approved for refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.
Open in Who Shared Issue with article?
Show More